Jupiter Neurosciences Files Q2 2025 10-Q
Ticker: JUNS · Form: 10-Q · Filed: Aug 19, 2025 · CIK: 1679628
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
Jupiter Neurosciences filed its Q2 2025 10-Q. Financials are in.
AI Summary
Jupiter Neurosciences, Inc. filed its 10-Q for the period ending June 30, 2025. The filing details financial performance and operational updates for the company, which is involved in the pharmaceutical preparations sector. Key financial data and disclosures relevant to investors are included.
Why It Matters
This filing provides investors with the latest financial health and operational status of Jupiter Neurosciences, Inc., crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Jupiter Neurosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-06-30 — Reporting Period End (Quarterly financial data is reported as of this date.)
- 2025-08-19 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- JUPITER NEUROSCIENCES, INC. (company) — Filer
- 20250630 (date) — Reporting Period End Date
- 20250819 (date) — Filing Date
- 001-41265 (other) — SEC File Number
- Jupiter Orphan Therapeutics, Inc. (company) — Former Company Name
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the period ending June 30, 2025.
What is the company's SEC file number?
The SEC file number for Jupiter Neurosciences, Inc. is 001-41265.
What was the former name of Jupiter Neurosciences, Inc.?
The former name of Jupiter Neurosciences, Inc. was Jupiter Orphan Therapeutics, Inc.
On what date was this 10-Q filed?
This 10-Q was filed on August 19, 2025.
What is the Standard Industrial Classification code for Jupiter Neurosciences, Inc.?
The Standard Industrial Classification code for Jupiter Neurosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2025-08-18 19:06:03
Filing Documents
- form10-q.htm (10-Q) — 719KB
- ex31-1.htm (EX-31.1) — 12KB
- ex31-2.htm (EX-31.2) — 12KB
- ex32-1.htm (EX-32.1) — 7KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001641172-25-024684.txt ( ) — 4429KB
- juns-20250630.xsd (EX-101.SCH) — 35KB
- juns-20250630_cal.xml (EX-101.CAL) — 44KB
- juns-20250630_def.xml (EX-101.DEF) — 155KB
- juns-20250630_lab.xml (EX-101.LAB) — 351KB
- juns-20250630_pre.xml (EX-101.PRE) — 270KB
- form10-q_htm.xml (XML) — 548KB
Financial Statements (unaudited)
Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations 5 Condensed Consolidated Statement of Changes in Stockholders' Deficit 6 Condensed Consolidated Statements of Cash Flows 7 Notes to the Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.
Controls and Procedures
Controls and Procedures 29
– OTHER INFORMATION
PART II – OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 30 Item 1A.
Risk Factors
Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 30
Signatures
Signatures 31 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this Quarterly Report on Form 10-Q may constitute "forward-looking statements" for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following risks, uncertainties and other factors: We are early in our development efforts, with a limited operating history, and have no products approved for commercial sale; We have not generated any revenue from product sales to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future; Our ability to gener
Business
Business Segment Business segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company's chief operating decision maker ("CODM") and relied upon when making decisions regarding resource allocation and assessing performance. When evaluating the Company's financial performance, the CODM reviews total revenues, total expenses, and expenses by functional classification, using this information to make decisions on a company-wide basis. The Company views its operations and manages its business in two operating segments: (i) the production and sale of premium nutritional supplements, and (ii) pharmaceutical operations focused on the development of drug candidates. Use of Estimates Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material. The Company bases its estimates on historical experience and other assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Significant estimates during the three and six month periods ended June 30, 2025 and 2024 include valuation of share based arrangements and those related to the recognition and disclosure of income taxes. Cash The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. From time to time, the Company has cash and cash equivalent balances in excess of the FDIC insured limit of $ 250,000 . As of June 30, 2025 cash and cash equivalent balances in excess of